The Relationship Between Metformin and Serum Prostate-Specific Antigen Levels

Area of Science:

• Endocrinology
• Urology
• Oncology

Background:

• Metformin is a primary oral medication for type 2 diabetes.
• Emerging research suggests metformin may have a role in prostate cancer chemoprevention.
• The direct impact of metformin on prostate biology remains unclear.

Purpose of the Study:

• To investigate the association between metformin dosage and serum prostate-specific antigen (PSA) levels in men with type 2 diabetes.
• To determine if metformin influences PSA, a key biomarker for prostate cancer.

Main Methods:

• A cross-sectional study included 326 men with type 2 diabetes and no history of prostate cancer.
• Exclusion criteria included PSA ≥10 ng/ml or metformin use >2,550 mg/day.
• Multivariate linear regression analyzed the relationship between metformin dose and log-PSA.

Main Results:

• Metformin dose was inversely associated with PSA levels, with an 8% decrease per 500 mg/day increase (P=0.011).
• This inverse association was more pronounced in men with diabetes for ≥6 years (-12% per 500 mg/day metformin, P=0.002).
• No significant association was found between PSA and other antihyperglycemic agents like sulfonylureas or thiazolidinediones.

Conclusions:

• Metformin dose-dependently and inversely correlates with serum PSA levels, independent of other diabetes medications.
• Further research is warranted to explore metformin's potential dose-dependent benefits in preventing and managing prostate cancer.